Rescuing Dendritic Cells from Adjuvant Toxicity: Liposomal Ginsenoside Rh2 as a Dual-Action Strategy for Enhanced...

Area of Science:

• Immunology
• Pharmacology
• Biochemistry

Background:

• Antigen-presenting cell (APC) cytotoxicity impedes vaccine adjuvant development.
• Novel adjuvants are needed to enhance vaccine efficacy and safety.

Purpose of the Study:

• To investigate the protective effects of liposome-encapsulated ginsenoside Rh2 (LP-Rh2) against cytotoxic immunostimulants.
• To elucidate the mechanisms underlying LP-Rh2's protective action on dendritic cells (DCs).

Main Methods:

• Transcriptomic and metabolomic profiling.
• Cellular functional assays assessing mitochondrial function and apoptosis.
• In vivo animal studies evaluating APC activation and immune responses.
• Serum biochemistry and histopathological analyses for toxicity assessment.

Main Results:

• LP-Rh2 ameliorated mitochondrial dysfunction and early apoptosis in DCs induced by liposomal simvastatin (LP-SIM).
• LP-Rh2 enhanced mitochondrial membrane potential and ATP production.
• Co-administration of LP-Rh2 and LP-SIM boosted APC activation and immune responses in vivo.
• No significant toxic pathological changes were observed.

Conclusions:

• LP-Rh2 protects DCs by regulating mitochondrial function and apoptosis, improving biosafety.
• LP-Rh2 shows potential as a protective adjuvant, synergizing with LP-SIM to enhance immune responses.
• LP-Rh2 may overcome APC-associated cytotoxicity, advancing vaccine adjuvant development.